Overheard: Why these 3 startups relocated to Houston

eavesdropping at the houston innovation awards gala

Here's why three New to Hou finalists from the Houston Innovation Awards have committed to Houston. Photo via Getty Images

Houston is attracting more and more businesses big and small, old and new. So much that it seemed worthy of an award for the Houston Innovation Awards Gala.

The awards event, which is on November 9 and hosted by InnovationMap and Houston Exponential at the Ion, is honoring five finalists selected by judges — and naming one winner — who have recently relocated or significantly expanded to Houston.

Here's why three of these New to Hou finalists have committed to Houston.

"The move to the Houston area allowed us to be much closer to our strategic partners, customers and suppliers. We are also impressed by the vast talent pool in the area. Houston has a highly skilled workforce with diverse experiences, particularly in oil and gas, petrochemicals, and a broad range of technical areas."

Photo courtesy

— Jay Manouchehri, CEO of Fluence Analytics, which relocated from Louisiana to Stafford last year, just outside of Houston. "We have been able to engage very actively with many customers since the move and also have developed valuable supplier relationships."

"In 2019, Chevron and EIC (both Houston based) became investors and we already had a lot of US clients, so we wanted to create a Houston footprint."

Photo courtesy

— John van Pol, co-founder and CEO of INGU, which opened its new Houston office in 2021. Van Pol adds that the pandemic delayed their expansion initially.

"Houston has a quickly-growing biotechnology sector and already has existing oil and gas talent, making it an ideal place to find the people we need to grow our business."

Photo courtesy

— Zimri T. Hinshaw, founder and CEO of BUCHA BIO, which relocated to Houston from New York in January 2022. "Our most prominent investor is Houston-based New Climate Ventures," he adds.

INGU Solutions has established its U.S. office in Houston — and is ready to tap into the city's energy industry with its revolutionary pipeline inspection-as-a-service model. Photo via ingu.com

Innovative Canadian company taps into Houston market to better serve energy customers

in the pipeline

On average, oil and gas pipelines are inspected every five years, which, considering pipelines in the United States are more than 60 years old, just isn't cutting it. Operators face costly and damaging leaks on cracks and incidences that are totally avoidable with more regular inspection. The issue is inspection isn't an easy process — unless INGU Solutions is involved.

The Alberta, Canada-based company has created a hardware component — called a Piper — that's about the size of a baseball. The device can be run through pipes of any size to inspect and detect internal issues. INGU has an inspection-as-a-service model so that whatever data is collected by the Pipers is analyzed and provided to clients without any more steps from them.

The idea for the device came to John van Pol, founder and CEO, who has a background in nuclear physics and founded the company in 2015. Now, he runs the company with his daughter, Anouk van Pol, who started as an analyst and working in the field for INGU and now serves the company as co-founder and COO.

The Piper is smaller than a baseball and can flow through any sized pipe used in the oil and gas industry. Photo via ingu.com

In 2017, INGU was selected to be a part of Chevron's inaugural Catalyst Program cohort and Chevron Technology Ventures — along with two other U.S. investors — contributed to the company's series A round in 2019. This led to INGU establishing its U.S. operations in Houston in order to grow their American team and to be closer to customers. Then, the pandemic hit.

“The idea was to be closer to our customers,” Anouk tells InnovationMap. “Houston is the oil and gas hub, and just being able to be in [our clients'] offices and be there in person it just helps. I hope at one point COVID passes and that we can make use out of it a bit more.

"The other thing is you open up your market on the hiring side," she says, adding that the company has two U.S. employees now.

INGU first had an office in The Cannon, but now operates locally at The Ion in the Common Desk coworking space with an office suite to support its local team. In 2019, the company was named to Plug and Play's inaugural Houston cohort and as a most-promising business by Rice Alliance at OTC.

Anouk, who was selected for Forbes 30 Under 30 in energy in 2020, and her father both split their time between Houston and Alberta, usually alternating so that the van Pols have a presence in each office at all times, but both are currently in town for the 34th annual Pipeline Pigging and Integrity Management conference, or PPIM. It's the OTC for the pipeline industry, Anouk says.

Ahead of the conference and despite the challenges the pandemic has posed for INGU, Anouk says the company has seen significant growth over the past two years.

"We grew 60 percent last year," she says. "which is pretty good for what's been happening over the past two years."

From a hardware perspective, the pandemic's impact has been relatively small. The Pipers are designed with off-the-shelf materials, which INGU stocked up on — avoiding any supply chain shortages. Additionally, INGU can send the devices to pipeline operators, who can deploy them while the devices send the collected data directly to INGU.

Anouk van Pol is the company's COO. Photo via LinkedIn

The company, which anticipates a secondary series A round this year in addition to tripling its annual revenue, has an environmental, social, and governance, or ESG, component to its business. While half of INGU's clients are in the energy industry and Pipers contribute to reducing waste within oilfield operations, the other half of customers are within the water industry. Water infrastructure is 100 years old, and Anouk says about 6 billion gallons of water are wasted each day.

"That's 40 percent of all water, and because so much water is lost, you need more power and energy," Anouk says. "Where we see oil and gas is aimed at prevention in well condition, etc., the water market is doing a lot of leak protection."

In both industries, Pipers are preventing waste and allowing companies to make positive moves in their ESG plans.

INGU has clients all over the world and servicing these various types of pipes and businesses is growing INGU's database, which better benefits their inspection-as-a-service capabilities.

"The more we grow, the more we can and will learn, and then go in this self-fulfilling cycle," Anouk says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings